Initial results from ongoing phase II study suggest clinical activity of luspatercept in patients with MF-associated anemia.
Venetoclax alone or in combination with azacitidine was well tolerated in patients with relapsed/refractory MDS, with combination therapy achieving an ORR of 40% and estimated 12-month OS of 65%.
In patients with TP53-mutant MDS/AML, APR-246 plus azacitidine was active and generally well tolerated.
Interim findings demonstrate that APR-246 yields a high CR rate when combined with azacitidine in patients with MDS or AML with TP53 mutations.
Longer-term analysis of the MEDALIST study showed that more luspatercept-treated patients attained transfusion independence for ≥ 8 weeks any time during therapy compared with placebo.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.